OR WAIT 15 SECS
Agilent and BGI have announced that they are to develop methodologies for next-generation genome-wide association studies.
Agilent and BGI have announced that they are to develop methodologies for next-generation genome-wide association studies. These methodologies will in turn help scientists involved in disease and drug research.
Agilent and BGI have been working together over several years and the aim of this collaboration is to create a next-generation super exome using Agilent’s SureSelect technology. The super exome incorporates sequence regions believed to be more informative for specific human populations.
Hui Jiang, associate director of the science and technology department at BGI, commented, “BGI aims to develop research collaborations and provide support to scientists all over the world. Together with Agilent’s expertise, we can create more precise and accurate technology that can be deployed in large-scale research to better understand complex diseases, which may have differences between ethnicities.”
Robert Schueren, vice president and general manager of Agilent's genomics business, said, “Agilent has a comprehensive portfolio of market-leading solutions for genomics research. This partnership with BGI will not only add to this portfolio, but also further Agilent's mission to build products that enable life sciences discoveries and develop solutions that improve the human condition.”